Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

4 SC AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

18 Jun 2016 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for 4Sc AG

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

10 Jun 2016 Wright Reports 61 $75.00

4SC - INCREASED FOCUS ON CORE BUSINESS

4SC’s Q1 results highlight an increased focus on its core business of epigenetic research and commercialisation, resulting fr...

19 May 2016 Edison Investment Research 3 $10.00

EQUI-Peers: Biotech - Krebstherapien

EQUITS GmbH, Frankfurt, setzt ihre neue Analyse-Reihe 'EQUI-Peer' mit einer weiteren Peergroup-Analyse 'EQUI-Peer Biotech - ...

16 Dec 2015 EQUI.TS 9 $25.00

EQUI-Peer: Biotech - Cancer Therapies

EQUITS GmbH continues its innovative Research series. 'EQUI-Peer Biotech - Cancer therapies provides a peer group compariso...

16 Dec 2015 EQUI.TS 10 $25.00

4 Sc AG: Downgraded to Average

10 Dec 2015 Sadif Analytics Prime 3 $10.00

4SC AG - RESMINOSTAT REFOCUSED CANCER STRATEGY

4SC has fresh funds and a renewed clinical strategy for its lead epigenetic anti-cancer agent resminostat. A €29m (gross) cap...

09 Nov 2015 Edison Investment Research 2 $10.00

4 Sc AG: Downgraded to Risky

03 Aug 2015 Sadif Analytics Prime 3 $10.00

4 Sc AG: Upgraded to Average

06 May 2015 Sadif Analytics Prime 3 $10.00

4SC AG (VSC) - Financial and Strategic SWOT Analysis Review

4SC AG (VSC) - Financial and Strategic SWOT Analysis Review Summary 4SC AG (4SC) discovers and develops targeted therapies fo...

03 Mar 2015 GlobalData 52 $125.00